The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study

PURPOSE: Pamiparib is an investigational, selective, oral poly(ADP-ribose) polymerase 1/2 (PARP1/2) inhibitor that has demonstrated PARP–DNA complex trapping and CNS penetration in preclinical models, as well as preliminary anti-tumor activity in early-phase clinical studies. We investigated whether...

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, Song, Lin, Chester, Skrzypczyk-Ostaszewicz, Anna, Bulat, Iurie, Maglakelidze, Marina, Skarbova, Viera, Andreu-Vieyra, Claudia, Sahasranaman, Srikumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149352/
https://www.ncbi.nlm.nih.gov/pubmed/33772633
http://dx.doi.org/10.1007/s00280-021-04253-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149352/
https://www.ncbi.nlm.nih.gov/pubmed/33772633
http://dx.doi.org/10.1007/s00280-021-04253-x

Ejemplares similares